The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Molecular diagnostics of neurodegenerative disorders
Open accessAbstract
Molecular diagnostics provide a powerful method to detect and diagnose various neurological diseases such as Alzheimer's and Parkinson's disease. The confirmation of such diagnosis allows early detection and subsequent medical counseling that help specific patients to undergo clinically important drug trials. This provides a medical pathway to have better insight of neurogenesis and eventual cure of the neurodegenerative diseases. In this short review, we present recent advances in molecular diagnostics especially biomarkers and imaging spectroscopy for neurological diseases. We describe advances made in Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD), and finally present a perspective on the future directions to provide a framework for further developments and refinements of molecular diagnostics to combat neurodegenerative disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Diagnosis of neurodegenerative diseases is usually based on subjective cognitive tests in combination with neuroimaging [131–133], but the current techniques are not able to successfully diagnose these diseases in their earlier stages, when the pathology is already present but does not cause symptoms yet.”
From Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation (2019) · cites this paper as [132]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864 · cited 1×
“Proteases that are involved in the breakdown of APP, are α-, β-, and γ- secretases (Hardy and Selkoe, 2002; Rachakonda et al., 2004).”
BackgroundAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
DeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adamson, J., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.011 · Cited by 4,936
Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481 · cited 1×
“This finding provided additional evidence that PINK1 mutations are associated with PARK6 (Valente et al., 2004).”
BackgroundMutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibáñez, P., Joosse, M., et al. (2003) · Science · doi:10.1126/science.1077209 · Cited by 2,854
The ubiquitin pathway in Parkinson's disease
Leroy, E., Boyer, R., Auburger, G. W. J., Leube, B., Ulm, G., Mezey, É., Harta, G., Brownstein, M., Jonnalagada, S., Chernova, T., et al. (1998) · Nature · doi:10.1038/26652 · Cited by 1,599
Alzheimer’s disease β-amyloid peptides are released in association with exosomes
Rajendran, L., Honsho, M., Zahn, T. R., Keller, P., Geiger, K. D., Verkade, P., & Simons, K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603838103 · Cited by 1,343 · cited 1×
“It has been reported that exosomal amyloid peptides accumulate in the brain plaques of AD patients (Rajendran et al., 2006) and tau phosphorylated at Thr-181, an established biomarker for AD, is present at elevated levels in exosomes isolated from cerebrospinal fluid specimens of AD patients with…”
BackgroundPlasma phospholipids identify antecedent memory impairment in older adults
Mapstone, M. E., Cheema, A. K., Fiandaca, M. S., Zhong, X., Mhyre, T. R., MacArthur, L. H., Hall, W. J., Fisher, S. G., Peterson, D. R., Haley, J. M., et al. (2014) · Nature Medicine · doi:10.1038/nm.3466 · Cited by 1,060
Review Article: Genetics of Alzheimer Disease
Bekris, L. M., Yu, C.-E., Bird, T. D., & Tsuang, D. W. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988710383571 · Cited by 1,029 · cited 1×
“In addition to the mutations mentioned above, which can cause AD, the E4 allele of the ApoE is associated with the sporadic forms of AD (Bekris et al., 2010).”
BackgroundSaman, S., Kim, W., Raya, M., Visnick, Y., Miro, S., Saman, S., Jackson, B., McKee, A. C., Alvarez, V. E., Lee, N. C. Y., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.277061 · Cited by 985
Flagged first, then by citations
Research works printed but not linked: 1
- Duyckaerts, 2003, Lewy bodies, a misleading marker for Parkinson's disease?, Bull. Acad. Natl. Med., 187, 277
Cited by
Sorted by citations
Items 101–164 of 164
Baran, A. M., Nowowiejska, J., Hermanowicz, J. M., Sieklucka, B., Krahel, J. A., Kiluk, P., Pawlak, D., & Flisiak, I. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11175044 · Cited by 6
“They are defined as such in which loss of neuronal tissue occurs [9].”
BackgroundAdeola, H. A., Wyk, J. C. V., Arowolo, A., & Khumalo, N. P. (2018) · IntechOpen eBooks · doi:10.5772/intechopen.77215 · Cited by 6
“Both conditions result in irreversible brain damage and early death and hair abnormalities seen in these patients help to differentiate these conditions from other NDs [60].”
BackgroundNanosensors-Assisted Quantitative Analysis of Biochemical Processes in Droplets
Belyaev, D., Schütt, J., Ibarlucea, B., Rim, T., Baraban, L., & Cuniberti, G. (2020) · Micromachines · doi:10.3390/mi11020138 · Cited by 6
Human Detection and Biometric Authentication with Ambient Sensors
Andrews, J., & Li, J. (2022) · Springer eBooks · doi:10.1007/978-3-030-99383-2_2 · Cited by 6
Smart nanophotonics for enzyme-driven drug resistance sensing and controlled therapeutic release
Taha, B. A., Addie, A. J., Al-Rawi, M. A., Haider, A. J., Yadav, A. K., Bhatia, D. D., Jabir, M. S., Ibnaouf, K. H., & Arsad, N. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107488 · Cited by 5
Diagnosis and management of neurodegenerative diseases
Kagawad, P., Bhandurge, P. J., & Gharge, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28822-7.00020-9 · Cited by 5
Jiang-yu, H., Hao, X., Fatima, M., Chauhdary, Z., Jamshed, A., Rahman, H. M. A., Siddique, R., Asif, M., Rana, S., & Hussain, L. (2024) · Dose-Response · doi:10.1177/15593258241282020 · Cited by 5
“Recent studies have demonstrated that ferulic acid (FA) reduced neuronal in fl ammation and improved behavioral impairments in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Parkinson mice model.”
BackgroundThe promise and challenges of extracellular vesicles in the diagnosis of neurodegenerative diseases
Hagey, D. W., & Andaloussi, S. E. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00014-x · Cited by 5
Neurological Biomarkers and Neuroinformatics
Solodkin, A., Zimmermann, J., McIntosh, A. R., Stefanovski, L., & Ritter, P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-804078-2.00001-5 · Cited by 6
Editorial: Molecular Diagnostics in the Detection of Neurodegenerative Disorders
Agrawal, M., & Cho, W. C. S. (2017) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2017.00010 · Cited by 5
“Such conditions result in the disorders of the central nervous system which eventually lead to the progressive loss of neural tissues including death of neurons (Agrawal and Biswas, 2015).”
Self-citationPOCT devices for neurodegenerative disorders: from lab to clinics
Parihar, A., Choudhary, N. K., & Khan, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95539-3.00015-6 · Cited by 5
Khan, Y. F., & Kaushik, B. (2022) · Lecture notes on data engineering and communications technologies · doi:10.1007/978-981-16-8403-6_7 · Cited by 4
Neuroprotective Effect of Boswellia serrata against 3-NP Induced Experimental Huntington’s Disease
Kumar, V., Sharma, C., Taleuzzaman, M., Nagarajan, K., Haque, A., Bhatia, M., Khan, S., Salkini, M. A., & Bhatt, P. (2024) · Current Bioactive Compounds · doi:10.2174/0115734072272233231119161319 · Cited by 4
Rajput, R., Kaur, R., Chadha, R., Mani, S., Rachana, R., Kaur, H., & Singh, M. (2018) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-5225-5282-6.ch001 · Cited by 4
Improper Proteostasis: Can It Serve as Biomarkers for Neurodegenerative Diseases?
Dubey, A. R., Patwa, S. M., Kinger, S., Jagtap, Y. A., Kumar, P., Singh, S., Dhiman, R., Jha, H. C., & Mishra, A. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02775-w · Cited by 3
“Based on their expertise, medical practitioners can carefully assess these test results, past medical history, and perceived symptoms of patients to diagnose a particular condition [31].”
BackgroundNeurodegenerative Diseases as Protein Folding Disorders
Baker, J. D., Webster, J. M., Shelton, L. B., Koren, J., Uversky, V. N., Blair, L. J., & Dickey, C. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811304-2.00009-2 · Cited by 3
Tatar, A.-S., Colniță, A., Brezeștean, I.-A., & Boca, S. (2026) · Biophysical Reviews · doi:10.1007/s12551-026-01428-9 · Cited by 2
“…2020; Song et al. 2011; Jack et al. 2010), based on molecules that are present in the CerebroSpinal Fluid (CSF), blood/ plasma, and other bodily fluids, known as biomarkers, measurable indicators of a biological state or condition (Brazaca et al. 2020; Ghidoni et al. 2018; Agrawal and Biswas 2015).”
Upcoming diagnostic biomarkers with promising prospects in neurological disorders
Ahmad, W., Ali, A., Ali, A., Khan, S. I., Khan, S., & Husain, I. (2019) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13216 · Cited by 2
Novel Approaches to Address the Dual Challenges of Neurodegeneration and Aging
Zeng, C. (2023) · Trends journal of sciences research · doi:10.31586/jcn.2023.649 · Cited by 2
Biomarkers of oxidative stress and proteopathies in the diagnosis of neurodegenerative diseases
Микашинович, З. И., Телесманич, Н. Р., Smirnova, O. B., & Черногубова, Е. А. (2024) · Molekulyarnaya Meditsina (Molecular medicine) · doi:10.29296/24999490-2024-02-03 · Cited by 2
The Role of Cell-Free RNA in Clinical Diagnosis and Evaluation of Cell-Free RNA Extraction Methods
Le, A. P. H., & Ha, H. (2021) · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · doi:10.1007/978-3-030-75506-5_53 · Cited by 2
Krokidis, M. G. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-78787-5_8 · Cited by 2
Shivakumar, A. B., Mehak, S. F., Kumari, S., Saraf, V., & Gangadharan, G. (2022) · Springer eBooks · doi:10.1007/978-981-19-1352-5_14 · Cited by 2
Sampling methods and biomarkers for early detection of neurodegenerative disorders
Sharma, P., Parihar, A., & Khan, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95539-3.00004-1 · Cited by 2
Parkinson’s Disease Rating Scale Using Synchronization Analysis of Gait Dynamics
Asmarian, N., Ruzitalab, A., Erjaee, G. H., Farahi, M. H., & Asmarian, S. M. (2021) · BioMed Research International · doi:10.1155/2021/5651519 · Cited by 2
Alzheimer’s disease and Aβ pathways
Singh, A. S., & Chanu, M. T. (2021) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2021.12.3.0740 · Cited by 1
Christodoulou, C. C., Demetriou, C. A., & Zamba‐Papanicolaou, E. (2025) · Cells · doi:10.3390/cells14151195 · Cited by 1
“Several proteomic studies have been conducted, mostly in HD mouse models [6–14] or induced pluripotent stem cells (iPSCs) [15–25].”
Association between lipid levels and dementia risk among older Ghanaian adults
Appiah, F., Simpong, D. L., Marfo, E., Osei, G. N., Antwi, M. H., Manu, K. S., Dogah, J., & Bockarie, A. S. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261430772 · Cited by 1
“While these methods enhance diagnostic accuracy, particularly in determining dementia etiology, 4 – 6 they are often limited by cost, accessibility, and invasiveness, particularly CSF sampling.”
The Benson Complex Figure Test for the Differential Diagnosis of Dementias
Papadogiani, M., Fasilis, T., Despoti, A., Kamtsadeli, V., Hantzopoulou, M., Tsinia, N., Lykou, E., Chatziantoniou, L., Chousos, D., Siarkos, K., et al. (2026) · NeuroSci · doi:10.3390/neurosci7020038 · Cited by 1
“One of the key cognitive domains affected by dementia is visuoconstructional skills and visual memory [3,4].”
Biomarkers in Rare Genetic Diseases
Scotton, C., & Ferlini, A. (2016) · InTech eBooks · doi:10.5772/63354 · Cited by 1
“This would seem to indicate that the causative gene is still missing [40], and research in this area has therefore focused on the discovery of specific biomarkers able to assist clinical diagnosis and monitor the disease progression.”
Ogunniyi, A. O. (2020) · Nigerian Journal of Health Sciences · doi:10.4103/njhs.njhs_24_20 · Cited by 1
Neurobiosensors: novel approaches towards early diagnostics of neurodegenerative disorders
Parihar, A., Sharma, P., Choudhary, N. K., & Khan, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95539-3.00007-7 · Cited by 1
Nanodevices in neurological infections: an update
Babu, Y. S., Kumari, N., & Maruthi, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18574-8.00017-0 · Cited by 1
Early Diagnosis of Parkinson’s Disease: Utility of Animal Models
Saroj, N., Ahmad, M. Z., Kumari, B., Ali, M. Z., & Dholaniya, P. S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.107887 · Cited by 1
Concepts | No Membrane, No Problem: Cellular Organization by Biomolecular Condensates
Sang, C. C., Moore, G., & Lee, H. O. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819460-7.00329-7 · Cited by 1
Bhattacharjee, A., Jamal, T. B., Ahammad, I., Lamisa, A. B., Arefin, M. S., Chowdhury, Z. M., Hossain, M. U., Das, K. C., Keya, C. A., & Salimullah, M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.15.562440 · Cited by 1
Environmental Pollution: Increasing Risk of Neurodegenerative Diseases
Ikram, H., & Nangyal, H. (2020) · Apple Academic Press eBooks · doi:10.1201/9780429265013-9
Rajput, R., Kaur, R., Chadha, R., Mani, S., Rachana, R., Kaur, H., & Singh, M. (2022) · IGI Global eBooks · doi:10.4018/978-1-6684-5295-0.ch008
Development in diagnosis and treatment of Alzheimer’s disease
Shivam, K. (2016) · IOSR Journal of Pharmacy (IOSRPHR) · doi:10.9790/3013-06714350
“Other than these there are following scanning systems used in the diagnosis of AD [21, 22].”
Background(2019) · Elsevier eBooks · doi:10.1016/b978-0-12-802823-0.09988-0
Molecular Diagnostics and Immunological Markers of Neurodegenerative Disorders
Chakraborty, S. (2022) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815040913122010011
Approach to Understanding Brain Disorders and Improving Healthcare OutcomesPreprint
Lee, H. (2023) · doi:10.31234/osf.io/hwzfy
(2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91788-9.16001-6
Detection of genetic and epigenetic markers in neurodegenerative disorders
Ray, S. K., & Mukherjee, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95539-3.00009-0
Lu, W., Zhang, B., Wang, Q., Yu, H., Xu, J., & Liu, A. (2023) · Research Square · doi:10.21203/rs.3.rs-3316044/v1
Impact of the NAD+ salvage pathway on the motor system and bioenergetics
Lundt, S. (2023) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/96990
Vectorial-based analysis of dual-tracer PET imaging: A proof of concept
Avendaño‐Estrada, A., Casas, M. Á. O., & Avila-Rodriguez, M. A. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107705 · Cited by 1
Role of Co-Block Polymers in the Treatment of Neurodegenerative Diseases
Kaur, S., Ghosh, S., Sharma, G., Mishra, J., Joshi, R., Bhatti, G. K., & Bhatti, J. S. (2023) · Springer eBooks · doi:10.1007/978-981-99-6917-3_6
Cıva Maruziyetinin Nörodejeneratif Hastalıklar Üzerindeki Etkisi
Elif, D. U. R. U., Yalçın, H. T., Çakır, D. A., Baydar, T., & Erkekoğlu, P. (2024) · Hacettepe University Journal of the Faculty of Pharmacy · doi:10.52794/hujpharm.1353188
Parkinson’s Disease MRIs Analysis Using Neutrosophic-Entropy Segmentation Approach
Singh, P. (2023) · Brain informatics and health · doi:10.1007/978-981-99-9939-2_3
Parkinson’s Disease MRIs Analysis Using Fuzzy Clustering Approach
Singh, P. (2023) · Brain informatics and health · doi:10.1007/978-981-99-9939-2_2
Szmyt, K., Superson, M., Wilk-Trytko, K., Szymańska, K., Walczak, K., Samojedny, S., Mika, W., Krasnoborska, J., & Zarębska, J. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.72.51253
Future Directions and Challenges in Enzyme Research for Neurodegenerative Diseases
Rathi, K. M., Pingat, P., & Firdous, S. M. (2024) · Springer eBooks · doi:10.1007/978-981-97-6822-6_10
The Rules of Molecular Technique in Diseases Identification
Zulkifli, S. A. (2022) · Academic International Journal of Medical Sciences · doi:10.59675/m2022-04
Kumari, S. K. S., Dhiman, M. D. M., Sharma, M. S. M., Kumari, A. K. A., & Thakur, A. T. A. (2025) · International Journal of Pharmaceutical Research and Applications · doi:10.35629/4494-100220832090
Zolfaghari, S., Sarbaz, Y., & Makouei, S. (2025) · Biomedical Engineering Applications Basis and Communications · doi:10.4015/s1016237225500334
Sahu, S. K., Choudhury, S., Tiwari, M., Kumar, H., & Chowdhury, A. S. (2025) · Communications in computer and information science · doi:10.1007/978-3-031-93709-5_12
Ofosu, N. N., Luth, W., Genuis, S. K., Tymkow, K., Budiyanto, I., McGuckin, T., Campbell-Scherer, D. L., & Johnston, W. S. W. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-104139
Sedaghat, F. R., Ahmadi, S., Zahmat-dar, T. S., Saedi, S., & Kafil, H. S. (2026) · Nutrition and Dietary Supplements · doi:10.2147/nds.s587800
Alghrably, M., Sukareh, F. A., Khamis, L. M., Kahfi, J., Dhahri, M., Emwas, A.-H., Jaremko, M., & Lachowicz, J. I. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1759011
Bouvier‐Müller, A. (2020) · theses.fr (ABES) · doi:10.70675/2097d129z95aaz45f5zbf91z199fddefb42c
Nanotherapeutics targeting neuroinflammation
Chaulagain, B., Tagoe, B., Gothwal, A., Mahanta, A. K., Muolokwu, C. E., Lamsal, B., & Singh, J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33623-2.00013-1
Metadata
- Authors
- Agrawal, M., & Biswas, A.
- Affiliations
- University of Arkansas at Little Rock (US)
- University of Notre Dame (US)
- Corresponding author
- Agrawal, Megha
- Venue
- Frontiers in Molecular Biosciences
- Publisher
- Frontiers Media SA
- Published
- 2015-09-22
- Volume
- 2
- Pages
- 54-54
- ISSN
- 2296-889X (ISSN-L)
- PMC
- PMC4585189
- OpenAlex
- W1811596609
- Cited by
- 164
- References
- 77
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 18 · 2023: 24 · 2022: 31 · 2021: 13 · 2020: 17 · 2019: 11 · 2018: 15 · 2017: 7 · 2016: 10 · 2015: 2
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Frontiers in Molecular Biosciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- molecular diagnosis, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, biomarkers, hyperspectral imaging, early diagnosis, neurogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
